Ionis Pharmaceuticals in Carlsbad has advanced antisense oligonucleotide therapy from its Faraday Avenue headquarters since 1989. The NASDAQ-listed biotech (IONS) holds over 1,500 issued patents worldwide, directing RNA-targeted drug candidates through clinical trial endpoints supported by North County diagnostic imaging at SimonMed Imaging - Carlsbad. Five commercially marketed drugs — nusinersen for spinal muscular atrophy, eplontersen for hereditary transthyretin amyloidosis, olezarsen, tofersen, and inotersen — all originated from the campus near Palomar Airport Road. Ongoing collaborations with Novartis on lipoprotein(a)-targeting cardiovascular programs and with Roche on Huntington's disease therapies generate a pipeline prescribed through regional health systems, with Kaiser Permanente Carlsbad Medical Offices among the local prescribing networks. The proprietary 2'-O-methoxyethyl sugar modification platform increases RNA-binding affinity and nuclease resistance, enabling once-monthly subcutaneous dosing for conditions previously requiring weekly intravenous delivery.